Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 22 min 30 sec ago

Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer

Mon, 07/07/2014 - 21:24
Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase...
Biopharmaceuticals, Oncology, Regulatory
Bayer, Nexavar, thyroid carcinoma

Provista Diagnostics, Inc. Appoints Rao V. Mulpuri, PhD, MBA, as Chief Operating Officer

Mon, 07/07/2014 - 12:04
New York, NY, July 7, 2014 -- (Healthcare Sales & Marketing Network) -- Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, toda...
Diagnostics, Personnel
Provista Diagnostics

JenaValve Names David J. Drachman Chief Executive Officer

Mon, 07/07/2014 - 11:58
Cardiovascular Medical Device Industry Veteran to Lead JenaValve in Broader Commercialization of TAVI Systems for Treatment of Aortic Valve Disease IRVINE, Calif. & MUNICH--(Healthcare Sales & Marketing Network)--JenaValve Technology, Inc., a privately-...
Devices, Cardiology, Personnel
JenaValve Technology, TAVI, JenaValve, JenaClip

Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy

Thu, 07/03/2014 - 13:00
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s most advanced product candidate, HT-100 (delayed-relea...
Biopharmaceuticals, FDA
Akashi Therapeutics, fast track designation, HT-100, halofuginone

Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development

Thu, 07/03/2014 - 12:55
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Akashi Therapeutics, Inc. announced today that the Muscular Dystrophy Association (MDA) has made an investment through the MDA Venture Philanthropy program to help fund clinical development of HT-10...
Biopharmaceuticals, Venture Capital
Akashi Therapeutics, HT-100, halofuginone, Duchenne muscular dystrophy

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong